U.S., Oct. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07214935) titled 'A TQT Study of Effect of M2951 on Cardiac Repolarization' on Oct. 08.
Brief Summary: The purpose of this study is to assess potential effects of M2951 on cardiac repolarization (i.e. prolongation of QT interval).
Study Start Date: Nov. 08, 2022
Study Type: INTERVENTIONAL
Condition:
Healthy
Intervention:
DRUG: Placebo matched to M2951
Participants will receive single oral dose of placebo matched to M2951 in either of study periods (period 1 or period 2 or period 3 or period 4) under fasted conditions.
DRUG: Moxifloxacin
Participants will receive single oral dose of moxifloxacin in either of study periods (period 1 or period ...